|
1
|
Huber MA, Maier HJ, Alacakaptan M,
Wiedemann E, Braunger J, Boehmelt G, Madwed JB, Young ER, Marshall
DR, Pehamberger H, et al: BI 5700, a selective chemical inhibitor
of I B kinase 2, specifically suppresses epithelial-mesenchymal
transition and metastasis in mouse models of tumor progression.
Genes Cancer. 1:101–114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keklikoglou I, Koerner C, Schmidt C, Zhang
JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T,
Schneeweiss A, et al: MicroRNA-520/373 family functions as a tumor
suppressor in estrogen receptor negative breast cancer by targeting
NF-κB and TGF-β signaling pathways. Oncogene. 31:4150–4163. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reed CC, Waterhouse A, Kirby S, Kay P,
Owens RT, McQuillan DJ and Iozzo RV: Decorin prevents metastatic
spreading of breast cancer. Oncogene. 24:1104–1110. 2004.
View Article : Google Scholar
|
|
4
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shostak K and Chariot A: NF-κB, stem cells
and breast cancer: The links get stronger. Breast Cancer Res.
13:2142011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
May MJ and Ghosh S: Rel/NF-kappa B and I
kappa B proteins: An overview. Semin Cancer Biol. 8:63–73. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huber MA, Azoitei N, Baumann B, Grünert S,
Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-kappaB is
essential for epithelial-mesenchymal transition and metastasis in a
model of breast cancer progression. J Clin Invest. 114:569–581.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Syed V: TGF-β Signaling in Cancer. J Cell
Biochem. 117:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buck MB and Knabbe C: TGF-Beta Signaling
in Breast Cancer. Ann N Y Acad Sci. 1089:119–126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li J, Zhu H, Chen T, Dai G and Zou L:
TGF-β1 and BRCA2 expression are associated with clinical factors in
breast cancer. Cell Biochem Biophys. 60:245–248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buck MB: Prognostic significance of
transforming growth factor beta receptor II in estrogen
receptor-negative breast cancer patients. Clin Cancer Res.
10:491–498. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Figueroa JD, Flanders KC, Garcia-Closas M,
Anderson WF, Yang XR, Matsuno RK, Duggan MA, Pfeiffer RM, Ooshima
A, Cornelison R, et al: Expression of TGF-beta signaling factors in
invasive breast cancers: Relationships with age at diagnosis and
tumor characteristics. Breast Cancer Res Treat. 121:727–735. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Biglari A, Bataille D, Naumann U, Weller
M, Zirger J, Castro MG and Lowenstein PR: Effects of ectopic
decorin in modulating intracranial glioma progression in vivo, in a
rat syngeneic model. Cancer Gene Ther. 11:721–732. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hildebrand A, Romarís M, Rasmussen LM,
Heinegård D, Twardzik DR, Border WA and Ruoslahti E: Interaction of
the small interstitial proteoglycans biglycan, decorin and
fibromodulin with transforming growth factor beta. Biochem. J.
302:527–534. 1994.
|
|
15
|
Ranjzad P, Salem HK and Kingston PA:
Adenovirus-mediated gene transfer of fibromodulin inhibits
neointimal hyperplasia in an organ culture model of human saphenous
vein graft disease. Gene Ther. 16:1154–1162. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Troup S, Njue C, Kliewer EV, Parisien M,
Roskelley C, Chakravarti S, Roughley PJ, Murphy LC and Watson PH:
Reduced expression of the small leucine-rich proteoglycans,
lumican, and decorin is associated with poor outcome in
node-negative invasive breast cancer. Clin Cancer Res. 9:207–214.
2003.PubMed/NCBI
|
|
17
|
Goldoni S and Iozzo RV: Tumor
microenvironment: Modulation by decorin and related molecules
harboring leucine-rich tandem motifs. Int J Cancer. 123:2473–2479.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goldoni S, Seidler DG, Heath J, Fassan M,
Baffa R, Thakur ML, Owens RT, McQuillan DJ and Iozzo RV: An
antimetastatic role for decorin in breast cancer. Am J Pathol.
173:844–855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mohan RR, Tovey JC, Sharma A, Schultz GS,
Cowden JW and Tandon A: Targeted decorin gene therapy delivered
with adeno-associated virus effectively retards corneal
neovascularization in vivo. PLoS One. 6:e264322011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reed CC, Gauldie J and Iozzo RV:
Suppression of tumorigenicity by adenovirus-mediated gene transfer
of decorin. Oncogene. 21:3688–3695. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao J, Sime PJ, Bringas P Jr, Gauldie J
and Warburton D: Adenovirus-mediated decorin gene transfer prevents
TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol.
277:L412–L422. 1999.PubMed/NCBI
|
|
22
|
Rydell-Törmänen K, Andréasson K,
Hesselstrand R and Westergren-Thorsson G: Absence of fibromodulin
affects matrix composition, collagen deposition and cell turnover
in healthy and fibrotic lung parenchyma. Sci Rep. 4:63832014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soo C, Hu FY, Zhang X, Wang Y, Beanes SR,
Lorenz HP, Hedrick MH, Mackool RJ, Plaas A, Kim SJ, et al:
Differential expression of fibromodulin, a transforming growth
factor-beta modulator, in fetal skin development and scarless
repair. Am J Pathol. 157:423–433. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee YH and Schiemann WP: Fibromodulin
suppresses nuclear factor-kappaB activity by inducing the delayed
degradation of IKBA via a JNK-dependent pathway coupled to
fibroblast apoptosis. J Biol Chem. 286:6414–6422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Appleby CE, Kingston PA, David A, Gerdes
CA, Umaña P, Castro MG, Lowenstein PR and Heagerty AM: A novel
combination of promoter and enhancers increases transgene
expression in vascular smooth muscle cells in vitro and coronary
arteries in vivo after adenovirus-mediated gene transfer. Gene
Ther. 10:1616–1622. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Creating Standard Curves with Genomic DNA
or Plasmid DNA Templates for Use in Quantitative PCR. Applied
Biosystem support.
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pulaski BA and Ostrand-Rosenberg S: Mouse
4T1 breast tumor model. Curr Protoc Immunol Chapter. 20:Unit 20.2.
2001. View Article : Google Scholar
|
|
29
|
Sainio A, Nyman M, Lund R, Vuorikoski S,
Boström P, Laato M, Boström PJ and Järveläinen H: Lack of decorin
expression by human bladder cancer cells offers new tools in the
therapy of urothelial malignancies. PLoS One. 8:e761902013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barcellos-Hoff MH and Akhurst RJ:
Transforming growth factor-beta in breast cancer: Too much, too
late. Breast Cancer Res. 11:2022009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Israël A: The IKK complex: An integrator
of all signals that activate NF-kappaB? Trends in Cell Biol.
10:129–133. 2000. View Article : Google Scholar
|
|
32
|
Lee CH, Jeon YT, Kim SH and Song YS:
NF-kappaB as a potential molecular target for cancer therapy.
Biofactors. 29:19–35. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pahl HL: Activators and target genes of
Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Courtois G: The NF-kappaB signaling
pathway in human genetic diseases. Cell Mol Life Sci. 62:1682–1691.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Karin M and Ben-Neriah Y: Phosphorylation
Meets Ubiquitination: The control of NF-[kappa]B activity. Annu Rev
Immunol. 18:621–663. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baldwin AS Jr: Series Introduction: The
transcription factor NF-kappaB and human disease. J Clin Invest.
107:3–6. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rahman KW, Ali S, Aboukameel A, Sarkar SH,
Wang Z, Philip PA, Sakr WA and Raz A: Inactivation of NF-kappaB by
3,3′-diindolylmethane contributes to increased apoptosis induced by
chemotherapeutic agent in breast cancer cells. Mol Cancer Ther.
6:2757–2765. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tergaonkar V, Pando M, Vafa O, Wahl G and
Verma I: p53 stabilization is decreased upon NFkappaB activation: A
role for NFkappaB in acquisition of resistance to chemotherapy.
Cancer Cell. 1:493–503. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pickup M, Novitskiy S and Moses HL: The
roles of TGFβ in the tumour microenvironment. Nat Rev Cancer.
13:788–799. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hishida A, Iwata H, Hamajima N, Matsuo K,
Mizutani M, Iwase T, Miura S, Emi N, Hirose K and Tajima K:
Transforming growth factor B1 T29C polymorphism and breast cancer
risk in Japanese women. Breast Cancer. 10:63–69. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ständer M, Naumann U, Wick W and Weller M:
Transforming growth factor-beta and P-21: Multiple molecular
targets of decorin-mediated suppression of neoplastic growth. Cell
Tissue Res. 296:221–227. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stover DG, Bierie B and Moses HL: A
delicate balance: TGF-beta and the tumor microenvironment. J Cell
Biochem. 101:851–861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Boström P, Sainio A, Kakko T, Savontaus M,
Söderström M and Järveläinen H: Localization of decorin gene
expression in normal human breast tissue and in benign and
malignant tumors of the human breast. Histochem Cell Biol.
139:161–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Iozzo RV and Schaefer L: Proteoglycans in
health and disease: Novel regulatory signaling mechanisms evoked by
the small leucine-rich proteoglycans. FEBS J. 277:3864–3875. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng Z, Lee KS, Zhang X, Nguyen C, Hsu C,
Wang JZ, Rackohn TM, Enjamuri DR, Murphy M, Ting K and Soo C:
Fibromodulin-deficiency alters temporospatial expression patterns
of transforming growth factor-β ligands and receptors during adult
mouse skin wound healing. PLoS One. 9:e908172014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zheng Z, Nguyen C, Zhang X, Khorasani H,
Wang JZ, Zara JN, Chu F, Yin W, Pang S, Le A, et al: Delayed wound
closure in fibromodulin-deficient mice is associated with increased
TGF-β3 signaling. J Invest Dermatol. 131:769–778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roughley PJ: The structure and function of
cartilage proteoglycans. Eur Cells Mater. 12:92–101. 2006.
View Article : Google Scholar
|
|
48
|
Iozzo RV: Matrix proteoglycans: From
molecular design to cellular function. Annu Rev Biochem.
67:609–652. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kalamajski S and Oldberg Å: The role of
small leucine-rich proteoglycans in collagen fibrillogenesis.
Matrix Biol. 29:248–253. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Antonsson P, Heinegård D and Oldberg Å:
Structure and deduced amino acid sequence of the human fibromodulin
gene. Biochim Biophys Acta. 1174:204–206. 1993. View Article : Google Scholar : PubMed/NCBI
|
